- Home
- INCY vs YMM Comparison
INCY vs YMM Comparison
Compare INCY & YMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INCY | YMM |
|---|---|---|
| Founded | 1991 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0B | 12.3B |
| IPO Year | 1993 | 2021 |
Fundamental Metrics
Financial Performance| Metric | INCY | YMM |
|---|---|---|
| Price | $102.46 | $11.51 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 3 |
| Target Price | ★ $90.71 | $12.67 |
| AVG Volume (30 Days) | 2.0M | ★ 7.0M |
| Earning Date | 10-28-2025 | 11-17-2025 |
| Dividend Yield | N/A | ★ 1.67% |
| EPS Growth | ★ 3878.02 | 29.34 |
| EPS | ★ 5.90 | 0.53 |
| Revenue | ★ $4,813,105,000.00 | $1,751,813,549.00 |
| Revenue This Year | $19.59 | $11.64 |
| Revenue Next Year | $10.88 | $8.97 |
| P/E Ratio | ★ $17.37 | $21.94 |
| Revenue Growth | 18.09 | ★ 19.09 |
| 52 Week Low | $53.56 | $9.45 |
| 52 Week High | $109.28 | $14.07 |
Technical Indicators
Market Signals| Indicator | INCY | YMM |
|---|---|---|
| Relative Strength Index (RSI) | 54.83 | 47.00 |
| Support Level | $100.55 | $11.24 |
| Resistance Level | $107.61 | $11.44 |
| Average True Range (ATR) | 2.94 | 0.36 |
| MACD | -0.98 | 0.08 |
| Stochastic Oscillator | 45.19 | 95.59 |
Price Performance
Historical ComparisonAbout INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About YMM Full Truck Alliance Co. Ltd. (each representing 20)
Full Truck Alliance Co Ltd, through its subsidiaries, provides comprehensive services for shippers and truckers through its mobile and website platforms. Its principal operations are in the People's Republic of China. The group derives its revenues principally from shippers and trucker's use of its platforms in connection with freight matching services and value-added services.